| scholarly article | Q13442814 |
| P50 | author | David P Nicolau | Q97634314 |
| Joseph L Kuti | Q117238804 | ||
| P2093 | author name string | Jared L. Crandon | |
| P2860 | cites work | International Journal of Antimicrobial Agents | Q15724616 |
| Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 | ||
| Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh [...] | Q24643277 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. | Q30977541 | ||
| Hospital-acquired pneumonia: risk factors, microbiology, and treatment | Q31920726 | ||
| Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus | Q34073176 | ||
| Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus | Q34077052 | ||
| Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin | Q34107062 | ||
| Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections | Q34117827 | ||
| Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance | Q34547868 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. | Q35138007 | ||
| Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers | Q35537659 | ||
| Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods | Q35541702 | ||
| The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus | Q36381504 | ||
| Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States | Q36744770 | ||
| Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains | Q36744877 | ||
| Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model | Q37450779 | ||
| Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q37623755 | ||
| In vitro activity of telavancin against resistant gram-positive bacteria | Q39686121 | ||
| Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against Streptococcus pneumoniae in the Thigh Infection Model | Q39746333 | ||
| Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis | Q39827957 | ||
| Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 | ||
| Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies | Q41807543 | ||
| Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections | Q43270929 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| International study of the prevalence and outcomes of infection in intensive care units | Q44988294 | ||
| Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model | Q46156156 | ||
| In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative | Q46634713 | ||
| Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus | Q46907214 | ||
| Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. | Q54292737 | ||
| Effect of protein binding on antibiotic activity in vivo | Q71708867 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pneumonia | Q12192 |
| Staphylococcus aureus | Q188121 | ||
| vancomycin | Q424027 | ||
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| P304 | page(s) | 5115-5119 | |
| P577 | publication date | 2010-09-13 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model | |
| Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model | |||
| P478 | volume | 54 |
| Q36328108 | 3D printed bioceramics for dual antibiotic delivery to treat implant-associated bone infection |
| Q34810456 | A novel murine model of established Staphylococcal bone infection in the presence of a fracture fixation plate to study therapies utilizing antibiotic-laden spacers after revision surgery. |
| Q37119959 | Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms |
| Q33622963 | Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection |
| Q37696606 | Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia |
| Q36292752 | Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection |
| Q35941253 | Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model |
| Q50047637 | Disruption of staphylococcal aggregation protects against lethal lung injury. |
| Q38892614 | Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis |
| Q38266421 | Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection |
| Q36599959 | Genomic characterization and assessment of the virulence and antibiotic resistance of the novel species Paenibacillus sp. strain VT-400, a potentially pathogenic bacterium in the oral cavity of patients with hematological malignancies |
| Q57789750 | Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi |
| Q89222348 | Immunomimetic Designer Cells Protect Mice from MRSA Infection |
| Q36439072 | In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. |
| Q36558524 | In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice |
| Q42107088 | In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection |
| Q38646905 | Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review |
| Q40018152 | New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection |
| Q38728912 | Oral-Only Linezolid-Rifampin Is Highly Effective Compared with Other Antibiotics for Periprosthetic Joint Infection: Study of a Mouse Model |
| Q35859914 | Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model |
| Q38829519 | Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia |
| Q36018731 | Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions |
| Q38048845 | Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies. |
| Q35905561 | Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). |
| Q33788308 | Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens |
| Q38159966 | Telavancin: a review of its use in patients with nosocomial pneumonia |
| Q38575714 | Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions |
| Q34672655 | The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia |
| Q37263918 | Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection |
Search more.